- Home
- RDN vs GH Comparison
RDN vs GH Comparison
Compare RDN & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RDN | GH |
|---|---|---|
| Founded | 1977 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 22.9B |
| IPO Year | 2008 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RDN | GH |
|---|---|---|
| Price | $33.80 | $162.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 26 |
| Target Price | $44.67 | ★ $201.64 |
| AVG Volume (30 Days) | ★ 1.9M | 1.9M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | ★ 3.02% | N/A |
| EPS Growth | 5.61 | ★ 6.74 |
| EPS | ★ 1.74 | N/A |
| Revenue | ★ $1,197,084,000.00 | $982,021,000.00 |
| Revenue This Year | $92.73 | $38.25 |
| Revenue Next Year | $7.66 | $35.37 |
| P/E Ratio | $19.40 | ★ N/A |
| Revenue Growth | N/A | ★ 32.88 |
| 52 Week Low | $30.53 | $64.00 |
| 52 Week High | $41.05 | $191.05 |
Technical Indicators
Market Signals| Indicator | RDN | GH |
|---|---|---|
| Relative Strength Index (RSI) | 46.07 | 43.36 |
| Support Level | $31.64 | $153.88 |
| Resistance Level | $33.89 | $173.94 |
| Average True Range (ATR) | 0.96 | 7.52 |
| MACD | 0.22 | -2.22 |
| Stochastic Oscillator | 71.40 | 17.68 |
Price Performance
Historical ComparisonAbout RDN Radian Group Inc.
Radian Group Inc is engaged in mortgage and real estate services. It provides both credit-related mortgage insurance coverage and other products and services across the residential real estate and mortgage finance industries. It has one reportable segment, Mortgage Insurance, which primarily derives its revenue by providing private mortgage insurance on residential first-lien mortgage loans to mortgage lending institutions and mortgage credit investors.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.